Management Team

The C4X Discovery management team has significant drug discovery and development expertise and experience, with a track record of value creation.

Clive Dix, PhD

Chief Executive Officer

Clive has more than 30 years' experience in life science research, with over 20 years in senior pharmaceutical industry positions, and a degree and PhD in Pharmacology. His expertise includes an in-depth understanding of all facets of drug discovery and development, a broad knowledge of the science and commercial landscape of a variety of therapeutic areas, and solid experience of the pharmaceutical business and finance community supporting the sector.

Clive was co-founder and Chief Executive of Convergence Pharmaceuticals Ltd, which was acquired by Biogen in Jan 2015.

Clive was previously co-founder and Chief Executive of PowderMed Ltd, a vaccines development company acquired by Pfizer in November 2006; before that he was Senior Vice President, Research and Development and a Board member of PowderJect Pharmaceuticals plc until its acquisition by Chiron Vaccines in 2003. Clive began his career in industry at Ciba-Geigy and then GlaxoWellcome, where he left as UK Research Director in 2001. Clive is a recent past Chairman of the BioIndustry Association (BIA), is currently Non-Executive Chairman of Touchlight Genetics Ltd and Centauri Ltd, and Non-Executive Member of the Medicines Discovery Catapult Board.

Craig Fox, PhD

Chief Scientific Officer

Craig is an experienced biologist having worked on and managed many drug discovery and development projects during the last 18 years, from initial target selection right through to investigating clinical efficacy and safety in Ph II patient studies. Prior to joining C4X Discovery, Craig was director of Respiratory Research at Pulmagen Therapeutics, a clinical stage company spun-out of Argenta in 2010. Craig was part of the Etiologics Team that merged with Argenta Discovery in 2004 and prior to this he worked for Bayer as a Research Scientist. Craig has a PhD from Birmingham University and a first class biochemistry degree from the University of Surrey.

Charles Blundell, DPhil

Chief Technical Officer and Founder

Charles invented C4XD's core Conformetrix technology, founded the Company and led the spin-out from The University of Manchester in 2008 with Dr. Andrew Almond. Charles has been awarded multiple grants from top UK research councils during his career and has published over 20 research articles in leading scientific journals. He studied for his undergraduate masters degree and DPhil in Biochemistry at the University of Oxford (Keble College), graduating within the top 5 of his peer group.

Brad Hoy

Chief Financial Officer (Director)

Brad has more than 20 years’ experience in the pharmaceutical and biotechnology industries and has held a number of senior financial and general management positions in both the UK and US. Previously, Brad was Chief Financial Officer of Plethora Solutions Holdings plc, an AIM-listed specialty pharmaceutical company, Chief Executive Officer of Xcellsyz Limited, a UK venture capital-backed life science company, and Senior Director of Geron Corporation’s stem-cell focused UK subsidiary. Brad is a co-founder of Seven Hills Venture Partners, a life sciences advisory firm, and currently serves on the Board of Directors for e-Therapeutics plc.

Thorsten Nowak, PhD

VP Structural Design & Medicinal Chemistry

Thorsten is an experienced pharmaceutical researcher, having joined C4X Discovery from AstraZeneca plc, where he worked for 16 years in drug design and project management. Thorsten has a PhD from the University of Cambridge and a first class chemistry degree from the University of Heidelberg, Germany and has worked across a range of therapeutic areas and drug targets.

Martin Watson, PhD

VP Structural Analysis

Martin was one of the first employees of the Company, coming from AstraZeneca plc where he had worked for 4 years in the industrial application of NMR to drug discovery. He has a first class masters chemistry degree from the University of Birmingham and a PhD from the University of Sheffield. He has applied NMR techniques across a wide range of drug targets.

Alun McCarthy, PhD

VP Novel Target Biology and Genomics

Alun has over 30 years of pharmaceutical industry experience, including drug discovery & development, genetics and biomarker research. Alun was co-founder and CEO of both Adorial (in 2014) and of PGXIS (in 2007). Former roles at GlaxoSmithKline include Head of Translational Medicine & Genetics for Psychiatry, Director of Clinical Pharmacogenetics, and Medical Strategy Head for CV/Metabolic Diseases. Alun has managed staff on a global basis, and has significant experience of engaging with regulatory authorities in the US, Europe and Japan. He holds a BA (Biochemistry) from the University of Cambridge, and a PhD (Biochemistry) from Trinity College, Dublin.

Olivier Delrieu, MD, MSc, MBA

VP Clinical Development and Mathematics

Olivier is an inventor of the Taxonomy3® technology and has over 18 years of pharmaceutical industry and clinical medicine experience. Olivier was co-founder of Adorial Ltd (2014). Former roles at Adorial and PGXIS include and Director, Target Identification (2012-2015) and Head, Clinical Sciences (2008-2012). Former roles at GlaxoSmithKline include Director, Neurosciences Medicines Development Centre (2006-2008), Clinical Partner to Director of Genetic Utility and Research Statistical Unit (2002-2008) and Global Therapeutic Area Adviser, Genetic Research (2001-2006). Olivier was previously a researcher at INSERM (1991-2002), and a House Officer, specialising in neurology, at the University Hospital of Lille (1995-2001). He holds a Master degree in Human Genetics (Institute Pasteur, Paris), is a Medical Doctor (University Lille II) and holds an executive MBA (EDHEC Business School).